Evidence map›Paper›PMID 28126965›Full record

SynthesisHaematologica2017

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Sarah A Buckley, Brent L Wood, Megan Othus, Christopher S Hourigan, Celalettin Ustun, Michael A Linden, Todd E DeFor, Michele Malagola, Chloe Anthias, Veronika Valkova and 5 more

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06845592 (SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia), which is not on this map. Cited by 163 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 2 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06845592 narecruitingnot on this mapstarted 2025, after this paper: background citation

SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

TypeinterventionalSponsorUniversity Of PerugiaRan2025 to 2031Enrolled51ConditionsAcute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL, High Risk Leukaemia, Leukaemia RelapseArmstotal marrow/lymphoid irradiation
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 2 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  12. Trial
  13. Trial
  14. Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  15. Trial
  16. Trial
  17. Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  18. Article
  19. Review
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

Sarah A BuckleyHematology/Oncology Fellowship Program, University of Washington, Seattle, WA, USA buckleys@uw.edu.
Brent L WoodDivision of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Christopher S HouriganHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Celalettin UstunDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Michael A LindenDivision of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Todd E DeForBiostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Michele MalagolaUnit of Blood Diseases and Stem Cell Transplantation, University of Brescia, A.O. Spedali Civili, Italy.
Chloe AnthiasAnthony Nolan Research Institute, London, UK.
Veronika ValkovaInstitute of Haematology and Blood Transfusion, Prague, Czech Republic.
Christopher G KanakrySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bernd GruhnDepartment of Pediatrics, Jena University Hospital, Germany.
Francesco BuccisanoDepartment of Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy.
Beth DevinePharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
University of Minnesota · USUniversity of Washington · USFred Hutch Cancer Center · USNational Institutes of Health · USInstitute of Haematology and Blood Transfusion · CZJena University Hospital · DEPoliclinico Tor Vergata · ITRoyal Marsden Hospital · GBUniversity of Brescia · IT

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
NCATS NIH HHS UL1 TR002494NHLBI NIH HHS T32 HL007093
6 · The paper itself

Abstract

Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been associated with increased risk of relapse and death in patients with acute myeloid leukemia, but detection methodologies and results vary widely. We performed a systematic review and meta-analysis evaluating the prognostic role of minimal residual disease detected by polymerase chain reaction or multiparametric flow cytometry before transplant. We identified 19 articles published between January 2005 and June 2016 and extracted hazard ratios for leukemia-free survival, overall survival, and cumulative incidences of relapse and non-relapse mortality. Pre-transplant minimal residual disease was associated with worse leukemia-free survival (hazard ratio=2.76 [1.90-4.00]), overall survival (hazard ratio=2.36 [1.73-3.22]), and cumulative incidence of relapse (hazard ratio=3.65 [2.53-5.27]), but not non-relapse mortality (hazard ratio=1.12 [0.81-1.55]). These associations held regardless of detection method, conditioning intensity, and patient age. Adverse cytogenetics was not an independent risk factor for death or relapse. There was more heterogeneity among studies using flow cytometry-based than

Indexed as

Acute DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, MyeloidNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosisSurvival AnalysisTransplantation, Homologous

Identifiers

PMID28126965
PMCPMC5477605
OpenAlexW2582929611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.